Biomerica's inFoods® IBS Secures $300 National Medicare Payment Rate, European Revenue Jumps 45%
BMRA is trading near its 52-week low of $1.866 (11% above the low).
Summary
Biomerica Inc. reported its third-quarter fiscal 2026 financial results, showing a decline in net sales to $987,000 from $1.12 million year-over-year. Despite the overall revenue decrease, the company announced several significant operational advancements. Most notably, the Centers for Medicare & Medicaid Services (CMS) established a national Medicare payment rate of $300 for its inFoods® IBS test, effective January 1, 2026, providing crucial reimbursement clarity and expanding patient access. Additionally, European revenue surged 45% year-over-year, and its hp+detect™ product received UK regulatory registration and secured its first commercial European lab order, signaling strong international commercial momentum. These positive catalysts, particularly the CMS payment rate, are highly material for a company of Biomerica's size and could significantly impact future revenue and profitability, offsetting the reported sales decline. Traders will closely watch the company's execution on Medicare coverage and the commercial rollout of these key products.
At the time of this announcement, BMRA was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $1.87 to $4.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.